Navigation Links
Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
Date:7/24/2013

SUNNYVALE, Calif., July 24, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today announced that it will report financial results and recent developments for its second quarter ended June 30, 2013 after the NASDAQ Market closes on Wednesday, July 31, 2013.  The Company will conduct a conference call and audio webcast at 4:30 p.m ET on the same day.

Conference call and webcast details:

Date: July 31, 2013
Time: 4:30 PM ET
Listen via Internet: http://ir.pharmacyclics.com/events.cfm
Toll-free: (877) 303-7908
International: (678) 373-0875

Replay Number (Toll Free): (855) 859-2056
Replay Number (International): (404) 537-3406
Conference ID #: 23863642

A webcast replay will be available on the Pharmacyclics website for 30 days.

About Pharmacyclics
Pharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medical healthcare needs; and to identify promising product candidates based on scientific development and administrational expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

Presently, Pharmacyclics has three product candidates in clinical development and several preclinical molecules in lead optimization. The Company is committed to high standards of ethics, scientific rigor, and operational efficiency as it moves each of these programs to viable commercia
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Pharmacyclics Reports First Quarter 2013 Results
2. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
3. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
4. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
5. Pharmacyclics, Inc. Prices Public Offering of Common Stock
6. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
7. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
8. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
9. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
10. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
11. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... NEW YORK , January 15, 2014 ... BreedIT Ltd., the exclusive worldwide distributor of highly sophisticated ... that on January 7, 2014, the Company,s board of ... Ben-Zion Weiner as its new member of the ...
(Date:1/15/2014)... 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ... System as a non-invasive, wireless continuous glucose monitoring system, ... Chairman and Interim CEO of Echo Therapeutics, will present ... Conference. Mr. Doman will make a ...
(Date:1/15/2014)... Pharmaceuticals International, Inc. (NYSE: VRX and ... the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") with ... indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), for all ... Medical, Inc. (NASDAQ: SLTM ) ("Solta") at ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... 2011 Reportlinker.com announces that a new market research ... Pain Therapeutics - Drugs, Markets and Companies ... report describes the latest concepts of pathomechanisms of pain ... pharmacotherapies for pain. Major segments of the pain market ...
... Pharmacotherapy research is set to become vastly more ... Wolters Kluwer Pharma Solutions , parent of the ... scientific information and analytics to professionals in the pharmaceutical and ... access (OA) publishing option for authors submitting original research articles ...
Cached Medicine Technology:Reportlinker Adds Pain Therapeutics - Drugs, Markets and Companies 2Reportlinker Adds Pain Therapeutics - Drugs, Markets and Companies 3Adis Journals Embrace Open Access 2Adis Journals Embrace Open Access 3Adis Journals Embrace Open Access 4
(Date:4/24/2014)... and irrelevant, could offer an alternative to heart transplants ... Furtado, and her team from the Australian Regenerative Medicine ... fibroblast is a close relative to a cardiomyocyte, the ... research published today in Circulation Research , Dr ... due to their genetic program, and will aid in ...
(Date:4/24/2014)... national response to the epidemic of prescription opioid overdose ... Journal of Medicine by leaders of agencies in ... The commentary calls upon health care providers to expand ... reduce overdose deaths, and describes a number of misperceptions ... The commentary also discusses how medications can be used ...
(Date:4/24/2014)... It is better to give than to receive ... a new study suggests. , The study found that 15- ... giving their money to family members, are less likely to ... taking risks or keeping the money for themselves. , The ... National Academy of Sciences . , The study focused on ...
(Date:4/24/2014)... NH, 4/24/14) Dartmouth has been awarded one of ... serve as a Lead Academic Participating Site in its ... Award recipients are a select groups of investigators charged ... fewer cooperative groups., The NCTN grant system reflects recommendations ... It streamlines operations to achieve four goals:, ...
(Date:4/24/2014)... The National Science Foundation has awarded LSU ... for Undergraduates (REU) Site grant in the amount ... of undergraduates from diverse social and educational backgrounds, ... Orleans area. The project will provide students ... of 2014-16. It will be led by ...
Breaking Medicine News(10 mins):Health News:Boring cells could hold the key to heart disease 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 3Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 4Health News:Study: Altruistic adolescents less likely to become depressed 2Health News:Dartmouth awarded lead role in NCI clinical trials network 2Health News:Dartmouth awarded lead role in NCI clinical trials network 3
... Yealink ... ... America’s leading supplier of Voice over IP (VoIP) equipment and complete systems, today announced the launch ... phones is comprised of five different SIP based models that range in price from $72 USD ...
... At The Parker Center ... surgery. , ... 2010 -- In light of recent media coverage of teens and plastic surgery, including a Today ... a great opportunity to address the right way to approach cosmetic surgery for teens and young ...
... ... Shared Hosting Servers , ... Charlotte, NC (PRWEB) May 19, 2010 -- ORCS Web Inc., a specialist in ... solutions announced that Microsoft’s newly released WCF RIA Services for Silverlight 4 has ...
... ... Participation from Amicus Capital and Prominent Angel Investors. , ... (PRWEB) May 19, 2010 -- SeniorHomes.com , ... or senior housing, announced today that it received a $1.1 million of Series A ...
... Nearly 2.5 million ... Because nearly 90% of eye injuries are preventable with proper protective eyewear, Defog It antifog ... ... Nearly 2.5 million eye injuries occur each year in the United States, with almost half occurring ...
... examining expression of every human gene in clear cell renal ... Mayo Clinic,s campus in Florida have discovered gene signatures they ... difficult-to-treat kidney cancer . In the May ... they have discovered: a biological pathway signature of ccRCC for ...
Cached Medicine News:Health News:VoIP Supply Adds Yealink IP Phones 2Health News:With the Right Approach, Plastic Surgery for Teens and Young Adults is Now a Positive Experience 2Health News:With the Right Approach, Plastic Surgery for Teens and Young Adults is Now a Positive Experience 3Health News:With the Right Approach, Plastic Surgery for Teens and Young Adults is Now a Positive Experience 4Health News:With the Right Approach, Plastic Surgery for Teens and Young Adults is Now a Positive Experience 5Health News:ORCS Web, Inc Makes Available WCF RIA Services 2Health News:SeniorHomes.com Closes $1.1 Million Series A Round of Investment Financing 2Health News:Eye Protection at Home Could Help Prevent 1 Million Home Eye Injures: Tips from Defog It Antifog During National Healthy Vision Month 2010 2Health News:Eye Protection at Home Could Help Prevent 1 Million Home Eye Injures: Tips from Defog It Antifog During National Healthy Vision Month 2010 3Health News:Mayo Clinic researchers find genetic secrets to common kidney cancer 2Health News:Mayo Clinic researchers find genetic secrets to common kidney cancer 3Health News:Mayo Clinic researchers find genetic secrets to common kidney cancer 4
The new, single-use 26 mL applicator is latex-free, hands-off and sterile to help prevent cross-contamination. The applicator is designed for a smooth delivery of the solution for larger surgical pro...
... Anti-HCV Low Titer Performance Panel consists of ... to strong positive for antibodies to the ... for use by manufacturers and diagnostic laboratories ... from all major test systems are included ...
Comprised of a monofilament polypropylene mesh coated with hydrophilic porcine collagen, Pelvitex™ mesh is clinically proven coating to enhance the healing process, along with the strength and d...
... a biological material derived from ... for excellent suppleness and strength. ... ensure high levels of quality ... enhances the biocompatibility, performance and ...
Medicine Products: